Background: Advances in autoimmune hepatitis that transform current concepts of pathogenesis and management can be anticipated as products of ongoing investigations driven by unmet clinical needs and an evolving biotechnology.
| INTRODUCTION
Transformative advances in autoimmune hepatitis are milestones in understanding that promise to impact on future management and investigation. They are products of a continuum of clinical and laboratory observations and technological improvements that are defining the antigenic triggers, genetic predispositions and homeostatic disruptions that favour loss of self-tolerance. 1 They are products of population-based epidemiological studies that have suggested associations between the environment and the disease, [2] [3] [4] and they are consequences of animal studies and clinical trials that are changing the paradigm of treatment from one of blanket immunosuppression to one of site-specific molecular and cellular intervention.
5
Recognition of cytochrome P450 2D6 (CYP2D6) as the principal autoantigen of one form of autoimmune hepatitis has been a transformative advance. 6, 7 It has been critical in developing animal models of the human disease [8] [9] [10] [11] and in understanding mechanisms for breaking the tolerance of self-antigens. 12, 13 Clarification of the cell populations that characterise the innate and adaptive immune responses in autoimmune hepatitis have led to discoveries of homeostatic imbalances that favour autoimmunity, [14] [15] [16] [17] and these insights into specific pathogenic pathways and perturbed cell populations have constituted another transformative advance that continues to fuel efforts at therapeutic manipulation. 5, 18 The future transformative advances can be anticipated as natural progressions of current knowledge and as products of unmet clinical needs and an evolving biotechnology.
The goal of this review was to describe the advances that are likely to be transformative in the future understanding and management of autoimmune hepatitis. The review anticipates investigational progress in autoimmune hepatitis and in autoimmune diseases outside autoimmune hepatitis that will provide applicable insights into pathogenesis and management.
| ME TH ODS
English abstracts were identified in PubMed using the search words "advances in autoimmune hepatitis", "epidemiology of autoimmune hepatitis", "genetics of autoimmune hepatitis", "epigenetics in autoimmunity", "intestinal microbiome and autoimmunity", and "novel treatment of autoimmune hepatitis". Abstracts judged pertinent to the review were identified; key aspects were recorded; and fulllength articles were selected from relevant abstracts. A secondary bibliography was developed from the references cited in the selected full-length articles, and additional PubMed searches were performed to expand the concepts developed in these articles. The discovery process was repeated, and a tertiary bibliography was developed after reviewing selected articles from the secondary bibliography.
The number of abstracts cited by PubMed from December 1963 to
June 2017 and reviewed for pertinence to this review during the primary, secondary and tertiary searches was 2830. Those judged most pertinent to the topic exceeded 500, and the number of full-length articles reviewed exceeded 150. 3 | RESULTS
| Anticipated advances in epidemiology
Population-based epidemiological studies have indicated that the incidence of autoimmune hepatitis varies widely between countries [19] [20] [21] [22] [23] [24] and between adults and children. 25, 26 The annual incidence of autoimmune hepatitis ranges from 0.67 cases per 100 000 persons in southern Israel 22 to 2.0 cases per 100 000 persons in New Zealand, 21 whereas the annual incidence in children is 0.23 cases per 100 000 persons in Canada 26 and 0.4 cases per 100 000 persons in the United States. 25 The incidence of autoimmune hepatitis has also been increasing in some countries. 24 In Spain, the annual incidence of autoimmune hepatitis has increased from 0.83 cases to 1.07 cases per 100 000 persons from 1990 to 2003, 27, 28 and in Denmark, the annual incidence has increased from 1.37 cases to 2.33 cases per 100 000 persons between 1994 and 2012 (Table 1) . 4 Coincident with the different and changing incidences has been disparity in the age of disease onset between countries. In the Netherlands, the median age of onset is 43 years in men and 48 years in women. 3 In Denmark, the peak age of onset is 70 years, 4 and in New Zealand, it is between 60 and 69 years. 21 These differences suggest that unrecognised factors outside the genotype are affecting disease occurrence. 24 
| Epidemiological implications
Autoimmune hepatitis has had codified diagnostic criteria since 1999, 29 and the population-based epidemiological studies that have demonstrated differences in the incidence of disease between countries have applied these criteria to well-defined populations during similar time frames. 3, 4, [19] [20] [21] Incomplete case detection and misdiagnosis can never be excluded, but unrecognised environmental factors that contribute to the disparities in incidence and peak age of onset must also be considered. These unidentified environmental factors may complement or supersede genetic predispositions for the disease (Table 1) . The changing incidence and clinical phenotype of autoimmune hepatitis compels the performance of population-based epidemiological studies that map susceptibility patterns in different countries, ethnic groups and sub-populations (Figure 1 ).
| Epidemiological precedents
Regional factors, including seasonal variations in sun exposure, activi- primary and secondary tobacco smoke in PBC, and they have stimulated investigation of xenobiotic associations with this disease. Similar studies have yet to be performed in autoimmune hepatitis.
Controlled interview-based surveys are needed to document exposure risks in autoimmune hepatitis, and they can be utilised in regions mapped as high or changing risk by well-designed population-based epidemiological studies. 36, 45 Clarification of the link between autoimmune hepatitis and the environment is an anticipated transformative advance that would aid in the prevention of disease in susceptible individuals and the protection of afflicted patients from disease progression.
| Anticipated advances in genetics
The association of autoimmune hepatitis with certain human leucocyte antigens (HLAs) has been recognised for decades in white North American and northern European patients [46] [47] [48] [49] [50] [51] [52] [53] [54] and confirmed recently by genome-wide association studies (GWAS) in northern European (Dutch) patients. 55 The next transformative advance in the genetics of autoimmune hepatitis will emerge from interrogations outside the major histocompatibility complex (MHC).
The ability to characterise subgroups of patients at risk for disease progression by GWAS and high density genotyping arrays [56] [57] [58] will facilitate the early identification of these patients and the institution of individualised interventions. 58 The products of risk-laden genes that contribute to the disruption of key pathogenic pathways might also be identified and considered for therapeutic targeting ( Figure 1 Open-source software 215, 237 DNA microarrays 236 Next-generation sequencing 214 Dysbiosis associated with RA, IBD, PSC, NASH and AIH 180, 187, 188, 190, 191 Permeable intestinal barrier in AIH 192 Translocation of gut-derived products in AIH, cirrhosis and diabetes 178, 179, 192 Mimicry of gut and self-antigens 198 Evolving therapeutic interventions [229] [230] [231] [232] [233] [234] [235] Identification of modifiable environmental factors to reduce incidence, prevalence and mortality Targeted interventions under evaluation in AIH and PBC 295, 296, 301 Pathogenic mechanisms being scrutinised and manipulated in liver disease 265, 268, 270 Expansion and transfer of regulatory T cells in experimental AIH 271, 273 AIH, autoimmune hepatitis; CpG, cytosine-phosphate-guanine sequence in gene; DNA, deoxyribonucleic acid; GWAS, genome-wide association studies; HSCs, hepatic stellate cells; IBD, inflammatory bowel disease; IL, interleukin; MHC, major histocompatibility complex; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; RA, rheumatoid arthritis; miRNA, micro ribonucleic acid; rRNA, ribosomal ribonucleic acid; miR, individual miRNA signature; SH2B3, Src homology 2-B adaptor protein 3 gene; SLE, systemic lupus erythematosus.
events that affect the regulation of hematopoiesis, cell migration, inflammatory activity and lymphocyte differentiation. [64] [65] [66] [67] [68] [69] inhibits T lymphocyte activation. 66 The rs3184504*A risk allele influences protein phosphorylation by the Janus kinase (JAK) family of tyrosine kinases. 66, 70 These effects may in turn affect cytokine production (tumour necrosis factor, interferon-gamma), the transduction of cytokine-mediated signals and the adaptive immune response. 63, 71 The same risk allele has been recognised in other immune-mediated diseases, including primary sclerosing cholangitis (PSC), 57 coeliac disease, 72 hypothyroidism, 73 rheumatoid arthritis 74 and type 1 diabetes mellitus. 75 Recognition and confirmation of the principal variant alleles associated with autoimmune hepatitis will allow functional analyses to proceed and possibly indicate pertinent gene products that could be selectively targeted. F I G U R E 1 Next-generation transformative advances that would satisfy unmet clinical needs in autoimmune hepatitis. The next generation of transformative advances can be predicted by current and anticipated investigational progress in identifying risk-laden allelic variants outside the major histocompatibility complex (MHC); clarifying the epigenetic effects on gene transcriptional activity associated with demethylation of deoxyribonucleic acid (DNA), histone modifications within chromatin and noncoding ribonucleic acid molecules (micro-RNAs); defining the pathogenicity of the intestinal microbiome; recognising the exogenous factors influencing disease behaviour; and developing site-directed molecular and cellular therapeutic interventions, including the expansion and adoptive transfer of regulatory T cells (Tregs). The key pathogenic processes that would be affected by these transformative advances are shown within the ellipse
HLA DRB1*0301 or HLA DRB1*0401 occurs in only 51% and 55% of white North American patients, respectively. 82 Children with autoimmune hepatitis may have different class II HLA associations than adults, 83 and patients in different countries or with different ethnicities within the same country may have disparate predisposing genetic factors. 81, 84, 85 These findings suggest that genetic analyses will have a limited impact on explaining the risk of autoimmune hepatitis and an applicability restricted to subgroups defined by age, race and location. The challenges are to identify variant alleles alone or in combination that influence disease behaviour by having functional expressions that can be targeted and to characterise the individuals with these genotypes.
Another challenge is to distinguish between differences related to risk-laden genes that differ because of ethnicity and those that differ because of cohort selection, detection method and statistical power. GWAS in northern European patients have suggested a possible association of the r36000782 allele of the caspase recruitment domain family member 10 (CARD10) gene with autoimmune hepatitis (P = 3.0 9 10
À6
), 63 whereas a multicentre cohort study in Japan based on a polymerase chain reaction-restriction length polymorphism method (PCR-RFLP) disclosed no association (P = .38). 86 Similar discordant observations between ethnically diverse cohorts have been described for polymorphisms of the cytotoxic T lymphocyte antigen-4 (CTLA-4) gene [87] [88] [89] [90] [91] and the tumour necrosis factor (TNF)
gene.
92-94
The pre-study hypothesis can also affect the number of comparisons analysed in the study and the statistical validity of the associations. The association between the rs7574865 allele of the signal transducer and activator of transcription (STAT) gene and autoimmune hepatitis in Japanese patients (P= .001) might be difficult to demonstrate if the loci had not been pre-selected. 95 Studies involving microarray technology should have a hypothesis-free approach in which multiple comparisons are made across the genome without areas of pre-defined interest. 58 Such studies require large patient and control cohorts of similar age and ethnicity, and international collaborations are required to make a truly transformative advance that applies genetic information to patient management. Importantly, hypothesis-free GWAS can generate data suitable for combination with other similar studies, and meta-analyses can empower the findings of individual studies. 58 Transformative advances in the genetics of autoimmune hepatitis will be difficult to achieve, but the biotechnology, study methods, and expectations are well founded and likely to drive these investigations.
| Anticipated advances in epigenetics
Epigenetic changes modulate the expression of genes without altering the sequence of deoxyribonucleic acid (DNA), and they can account for stable inherited phenotypic features. [96] [97] [98] Inheritability through cell divisions or progeny is a requirement of an epigenetic trait, 97 but any structural adaptation of a chromosomal region that affects gene activity is also epigenetic. 96, 99 Epigenetic modifications of gene activity may explain the difference between the observed risk for autoimmune hepatitis and the genetic factors implicated by GWAS. Epigenetic changes also exhibit plasticity, organ-specificity, and reversibility. 100, 101 The main epigenetic changes occur in the chromatin structure as a result of modifications in the methylation status of DNA 97, 102 and in the structure of the histone proteins by acetylation, methylation, phosphorylation, or ubiquitination of amino acid residues [103] [104] [105] ( Clarification of the epigenetic changes associated with autoimmune hepatitis could herald a fresh era of therapeutics that includes evidence-based dietary and environmental changes 168 and targeted molecular interventions that alter gene activity (Figure 1 ). (Table 1) . 191, 192 Investigations that strengthen the association of the intestinal microbiome with autoimmune hepatitis would transform current perceptions of pathogenesis and management.
| Intestinal microbiome and autoimmunity
Changes in the composition of the microflora by antibiotics, diet or disease can circumvent the normal tolerogenic responses to commensal bacteria and generate innate and adaptive immune responses that are pro-inflammatory. 193 Genetic factors can also influence the nature of the intestinal microbiome and character of the immune responses. 194, 195 Structural proteins (zona occludens 1 and occludin) that bind intestinal epithelial cells are reduced in autoimmune hepatitis, and the presence of lipopolysaccharide in the systemic circulation suggests altered permeability of the intestinal mucosal barrier (Table 1) . 192 Gut-derived reactive T lymphocytes in the pancreas and lymph nodes of patients and animal models with type 1 diabetes implicate a trans-intestinal pathway by which immune cells originating in the intestine can influence the systemic immune response. 178, 196, 197 Na€ ıve T lymphocytes may also be sensitised to the gut-derived microbial antigens in the systemic circulation. "Foreign" antigens from the intestine may have epitopes homologous to normal selfproteins, and they may generate a promiscuous adaptive immune response that breaks tolerance to self-antigens by molecular mimicry Transfer of expanded Tregs in AIH 271, 273 Anti-fibrotic interventions Hepatic stellate cells 304 Extracellular matrix 304 Angiotensin II inhibitors reduce fibrosis 278 Simtuzumab limits cross-linked collagen 283 Endocannabinoid agonists Cannabinoid receptors [287] [288] [289] [290] [291] Expand Tregs in experimental AIH 288 Immunosuppression in murine AIH 288 AIH, autoimmune hepatitis; BET, bromodomain and extra-terminal proteins; DNA, deoxyribonucleic acid; IL, interleukin; miRNA, micro ribonucleic acid; miR, individual miRNA signature; NAFLD, non-alcoholic fatty liver disease; NOX, nicotinamide adenine dinucleotide phosphate oxidase; Nrf2, nuclear factor-erythroid 2-related factor 2; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SH2B3, Src homology 2-B adaptor protein 3 gene; SLE, systemic lupus erythematosus; TIPE2, tumour necrosis factor-alpha-induced protein-8 like-2; TLR, toll-like receptors; Tregs, regulatory T cells.
( Figure 1) . The intestinal microbiome may also contribute to a gender bias in the development of autoimmune disease. 173 Male and female nonobese diabetic (NOD) mice have different intestinal microbiota, and this difference is lost after male castration. 202 Female NOD mice develop type 1 diabetes more frequently than male NOD mice, and this difference is lost in germ-free animals. 202 Colonisation of immature female NOD mice with the intestinal microflora from mature male NOD mice protects them from diabetes, and blockade of the androgen receptor in female NOD mice diminishes this effect. 203 These findings suggest that the female propensity for immunemediated disease in a genetically susceptible host may be influenced by the intestinal microflora. These microflora may in turn be shaped by sex hormones that they can also produce. and a community. 173 The human intestinal tract contains 10-11 trillion bacteria comprising 500-1500 different species distributed in the lumen and the mucosa. 175, [205] [206] [207] [208] [215] [216] [217] Antibiotics, medications, probiotic supplements, personal hygiene, medical history, advancing age and diet influence the composition of the microbiota in an individual, 173, 206, [218] [219] [220] and vaccination programmes, dietary habits and community sanitation influence the intestinal composition within communities. [221] [222] [223] [224] The intestinal microbiota differs in individuals living in rural and urban areas, 224, 225 and the microbiome varies with socioeconomic status. 225 These challenges are formidable, but their recognition is essential in developing experimental models, strengthening study designs, and improving biotechnology.
Cataloguing of the bacterial species within the intestine is a dynamic evolving process and a critical requirement for conducting research in this area. The Human Microbiome Project has defined the composition of the intestinal microbiota, and it has described factors that alter microbial composition and associate with health and disease. 226 Publicly available comprehensive databases 217, 227 and open-source software packages 215 have strengthened the ability to analyse results with updated catalogues, and microarrays have been designed to include explorative probes for unknown microbial sequences. 214 Awareness of the multiplicity of factors affecting composition of the intestinal microbiota allows studies to be designed that reduce the impact of confounders. The intestinal microbiome tends to be stable from late childhood through adulthood, whereas it becomes less diverse and more variable over short intervals with ageing. 206, 218, 219, 228 This foreknowledge can strengthen the design of clinical studies by directing the selection of cohorts matched for the predetermined confounders. The resources are available to conduct meaningful research of the intestinal microbiome in autoimmune hepatitis, and the investigational precedents in other immunemediated diseases compel its consideration.
| Transformative management strategies for autoimmune hepatitis
Antibiotics have reduced disease activity in a meta-analysis of 10 randomised clinical trials of patients with rheumatoid arthritis 229 and in a small randomised pilot study of PSC (Table 2) . 230 Probiotic supplements have expanded regulatory T cells in cell culture 231 and prevented type 1 diabetes in NOD mice. 232 Gelatin tannate, a protector of the intestinal mucosal barrier, has reduced the activity of experimental acute colitis and altered the composition of the intestinal microbiome in mice. 233 Intestinal re-colonisation in experimental colitis 234 and molecular blockade of TLRs in a murine model of SLE 235 have decreased inflammatory activity. The multiplicity of feasible interventions that may favourably alter the intestinal microbiome and improve immune-mediated disease is a testimony to the investigational interest and preliminary nature of these strategies.
The intestinal microbiome has already been implicated in the pathogenesis of autoimmune hepatitis, 191, 192 and this association must be strengthened by investigations in animal models and in patients with the disease. 173 Sequencing of the 16S rRNA gene can determine signature sequences that reconstruct the intestinal microbiome, 212, 213 and advances in microarray technology 214, 236 and open-source software packages 215, 237 can provide high-throughput platforms that recognise known and previously unknown microbial species. The antigenic triggers of autoimmune hepatitis are uncertain, and the intestinal microbiome constitutes a discovery field that could lead to transformative concepts of cause and management.
| Anticipated advances in management
Current immunosuppressive regimens have undirected and unsustainable actions, and they may fail to suppress inflammatory activity or prevent cirrhosis. during therapy (treatment failure), 238 and 14% improve but fail to normalise liver tests and liver tissue (partial response). 239 Treatment withdrawal is followed by relapse in 50-87%, 240-243 and 60-81% of patients become treatment-dependent. 241, 242 Autoimmune hepatitis progresses to cirrhosis in as many as 40%, 244 and 1%-6% of patients with cirrhosis develop hepatocellular carcinoma. 245, 246 Deficiencies in current management strategies can be improved, supplemented or replaced, and progress can be anticipated in each area.
| Key prospects for improved current management
The basic deficiency in managing autoimmune hepatitis is the lack of a biomarker that reflects suppression or elimination of the principal pathogenic mechanisms that sustain the disease. Autoimmune hepatitis can progress or exacerbate despite treatment to normal liver tests or liver tissue, [247] [248] [249] and an anticipated improvement in management will be characterisation of the treatment response by biomarkers that reflect immune reactivity, inflammatory response, fibrotic activity or apoptotic cell death. Serum levels of organ-specific miRNAs (miR-22 and miR-122) have already been proposed as biomarkers of inflammatory activity in autoimmune hepatitis, 148 and serum determinations of nitric oxide metabolites may emerge as biomarkers of hepatic inflammation and fibrosis. 250, 251 Other candidate biomarkers are the serum chemokines and cytokines. Tumour necrosis factor-alpha-induced protein-8 like-2 (TIPE2) inhibits signalling pathways that promote inflammatory and immune activity, 256, 257 and its expression in the peripheral blood mononuclear cells of a murine model of autoimmune hepatitis is decreased (Table 2) . 258 Furthermore, laboratory and histological features of inflammatory activity and the production of pro-inflammatory cytokines are increased when the murine model is based on TIPE2-deficient animals. 258 Agonists of TIPE2 activity are feasible molecular interventions that warrant consideration in the future management of autoimmune hepatitis.
Chemokines that modulate the trafficking of inflammatory and immune cells to sites of liver injury can affect injurious and reparative processes. 253, 259 Neutralising antibodies against specific chemokine ligands 260 and peptides 261 or pharmacological agents (cenicriviroc and maraviroc) [262] [263] [264] that block critical chemokine receptors have had preliminary successes in animal models and patients with diverse inflammatory and immune-mediated diseases (Table 2 ). The apoptosis of hepatocytes can also be targeted directly by caspase inhibitors. Anti-caspase therapy has reduced inflammation and fibrosis in animal models of NASH, 265 and it has improved liver tests in limited clinical trials involving patients with various liver diseases. 266, 267 Oxidative and nitrosative stresses that promote hepatocyte apoptosis, organelle dysfunction, and hepatic fibrosis 250 have been countered by antagonists of nicotinamide adenine dinucleotide phosphate oxidases (NOXs) which inhibit the generation of reactive oxygen (superoxide) and nitrogen (peroxynitrite) species in animal models (Table 2) . NOX antagonists have reduced the apoptosis of hepatocytes and limited hepatic fibrosis in rodents after bile duct ligation. 268, 269 Similarly, activators of nuclear factor-erythroid 2-related factor 2 (Nrf2) have promoted the expression of antioxidant genes, decreased oxidative stress, and reduced hepatic fibrosis in an animal model of NAFLD. 270 Regulatory T cells that are deficit in number or function may fail to modulate the inflammatory and fibrotic processes in autoimmune hepatitis, 14, 16 and this population has been targeted by adoptive transfer in animal models (Table 2) . [271] [272] [273] Adoptive transfer facilitates the induction and expansion ex vivo of antigen-specific regulatory T cells that can be re-infused. These cells can then induce other T lymphocytes to differentiate in vivo into secondary regulatory T cells that can function as memory cells, activate after antigen exposure, and maintain a durable immunomodulatory effect. 274 Angiotensin II stimulates collagen-producing genes, increases the secretion of transforming growth factor-beta (TGF-b) and promotes the activity of NOXs. 5,275 Molecular inhibitors of angiotensin II have reduced collagen deposition in bile duct-ligated rats [276] [277] [278] and decreased hepatic fibrosis in two of three clinical studies of patients with chronic hepatitis C (Table 2) . 275, 279, 280 Angiotensin II inhibitors have anti-fibrotic actions that might be realised in autoimmune hepatitis.
Lysyl oxidase-like enzymes (LOXLs) cross-link collagen fibrils and render them resistant to degradation by metalloproteinases. 281, 282 Monoclonal antibodies to LOXL2 (simtuzumab) have been well tolerated in an open label safety trial involving patients with advanced hepatic fibrosis, 283 and simtuzumab is a candidate anti-fibrotic intervention in chronic liver disease (Table 2) . 284 Hepatic fibrosis is stimulated by activating the cannabinoid CB1 receptors on HSCs, and it is inhibited by activating the cannabinoid CB2 receptors. 285 Rimonabant blocks the CB1 receptor, but this drug has been withdrawn because of severe neuropsychiatric side effects. 286 Next-generation antagonists of the CB1 receptor or agonists of the CB2 receptor are required to advance this anti-fibrotic therapy.
The endocannabinoid system can also influence the inflammatory and immune responses to liver injury (Table 2) . [287] [288] [289] [290] [291] Natural (delta 9-tetrahydrocannabinol) and endogenous (anandamide, 2-arachidonylglycerol) endocannabinoids can exert anti-inflammatory and immunosuppressive effects by activating the CB1 and CB2 receptors and expanding the regulatory T cell population in an experimental model of autoimmune hepatitis. 288 Inhibitors of the endocannabinoid hydrolysing enzyme, fatty acid amide hydrolase, can achieve similar results by impairing degradation of the endogenous endocannabinoids. 288 Agonists of the endocannabinoid system are now feasible interventions to evaluate as immunosuppressive strategies in autoimmune hepatitis. 
| Caveats of a changing paradigm

| OVERVIEW
The next-generation transformative advances in autoimmune hepatitis can be predicted by the progress already made in describing its variable incidence, genetic predisposition, and responsiveness to investigational site-specific molecular and cellular interventions. Findings in other immune-mediated systemic and liver-related diseases provide insights that should also drive progress. The disruption of homeostatic mechanisms that regulate lymphocyte activation, differentiation, proliferation, and migration is a pathogenic concept common to all autoimmune diseases, and discoveries that clarify and modify the pathways of inflammation, apoptosis, and fibrosis are potential stepping-stones for progress in autoimmune hepatitis regardless of their disease origin.
The identification of risk-laden genetic foci outside the MHC and the targeting of implicated gene products has been an area of progress in PBC. 58 Epigenetic analyses promise to unmask environmental cues that influence the onset and outcome of NAFLD and PBC, 96, 97 and the intestinal microbiome is emerging as a discovery field for antigens and activated immune cells that affect the inflammatory responses in PSC, NAFLD and autoimmune hepatitis. 173, 192 Population-based epidemiological studies in autoimmune hepati- 
